Annals of Oncology Advance Access published online on February 13, 2008
Annals of Oncology, doi:10.1093/annonc/mdn028
© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org
in this issue
| The first 10% of the full text of this article appears below. |
 |
Survival outcomes of taxanes in breast cancer
|
|---|
Despite the increased number of active agents, single-agent
taxane therapy remains one of the standard treatments for metastatic
breast cancer. Paclitaxel and docetaxel share similar chemical
structures and anti-tumor activities, but differ in non-hematologic
toxicity profiles. Since patients recruited to clinical trials
often have better performance status, Vu et al. [mdm527] compared
the overall survival in patients treated with single-agent paclitaxel
or docetaxel for
. . . [Full Text of this Article]
 |
KRAS in cetuximab-treated colorectal cancer
|
|---|
 |
Toll-like receptors in gastric lymphomas
|
|---|
 |
HSP90 in melanoma
|
|---|
 |
Quote
|
|---|

CiteULike
Connotea
Del.icio.us What's this?